Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis? Commentary

Nature Clinical Practice Neurology

Volumn 2, Issue 7, 2006, Pages 364-365

  Lindhorst, Scott ^a   Cudkowicz, Merit ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Pentoxifylline; Phosphodiesterase (PDE4B); Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; Riluzole

Indexed keywords

PENTOXIFYLLINE; PHOSPHODIESTERASE IV; PLACEBO; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ENZYME ACTIVITY; HOT FLUSH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MORTALITY; NAUSEA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SURVIVAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PENTOXIFYLLINE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33745595865     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0238     Document Type: Short Survey

References (5)

1. Rosen DR et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62
2. Emerit J et al. (2004) Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 58: 39-46
3. Miller et al. (2003) Riluzole for amyotrophic lateral sclerosis (ALS)/ motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 4: 191-206
4. Patel TB et al. (2001) Molecular biological approaches to unravel adenylyl cyclase signaling and function. Gene 269: 13-25
5. Lin HI et al. (2004) Pharmacological modulation of TNF production in macrophages. J Microbiol Immunol Infect 37: 8-15